CR11473A - Uso de 3,11 b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria - Google Patents

Uso de 3,11 b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria

Info

Publication number
CR11473A
CR11473A CR11473A CR11473A CR11473A CR 11473 A CR11473 A CR 11473A CR 11473 A CR11473 A CR 11473A CR 11473 A CR11473 A CR 11473A CR 11473 A CR11473 A CR 11473A
Authority
CR
Costa Rica
Prior art keywords
treatment
cis
multiple sclerosis
mielitis
dihidrotetrabenazine
Prior art date
Application number
CR11473A
Other languages
English (en)
Inventor
John Duffield
Original Assignee
Bioval Lab Internat Barbados Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioval Lab Internat Barbados Srl filed Critical Bioval Lab Internat Barbados Srl
Publication of CR11473A publication Critical patent/CR11473A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion estipula un compuesto para usar en el tratamiento de la esclerosis multiple donde ele compuesto es una 3, 11b-cis dihidrotetrabenazina de formula o una de sus sales farmaceuticas aceptables.
CR11473A 2007-11-02 2010-06-02 Uso de 3,11 b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria CR11473A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0721669.0A GB0721669D0 (en) 2007-11-02 2007-11-02 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
CR11473A true CR11473A (es) 2010-11-11

Family

ID=38834835

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11473A CR11473A (es) 2007-11-02 2010-06-02 Uso de 3,11 b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria

Country Status (18)

Country Link
US (1) US20110039877A1 (es)
EP (1) EP2207551A1 (es)
JP (1) JP2011502977A (es)
KR (1) KR20100074234A (es)
CN (1) CN101932323A (es)
AU (1) AU2008320603A1 (es)
CA (1) CA2702134A1 (es)
CO (1) CO6321285A2 (es)
CR (1) CR11473A (es)
EC (1) ECSP10010145A (es)
GB (1) GB0721669D0 (es)
IL (1) IL204990A0 (es)
MX (1) MX2010003980A (es)
NI (1) NI201000047A (es)
NZ (1) NZ584846A (es)
RU (1) RU2010116859A (es)
WO (1) WO2009056885A1 (es)
ZA (1) ZA201003037B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351247A1 (en) 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
EP3398602A1 (en) 2014-01-27 2018-11-07 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
RS61645B1 (sr) 2015-10-30 2021-04-29 Neurocrine Biosciences Inc Valbenazin ditozilat i njihovi polimorfi
JP6869988B2 (ja) * 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
CA3051830A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
US20070037800A1 (en) * 2005-06-23 2007-02-15 Envivo Pharmaceuticals, Inc. Method of treating neurological disorders using clotrimazole and derivatives thereof
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
ECSP10010145A (es) 2010-08-31
CA2702134A1 (en) 2009-05-07
CO6321285A2 (es) 2011-09-20
AU2008320603A1 (en) 2009-05-07
ZA201003037B (en) 2011-08-31
WO2009056885A1 (en) 2009-05-07
KR20100074234A (ko) 2010-07-01
EP2207551A1 (en) 2010-07-21
RU2010116859A (ru) 2011-12-10
IL204990A0 (en) 2010-11-30
NZ584846A (en) 2011-07-29
GB0721669D0 (en) 2007-12-12
US20110039877A1 (en) 2011-02-17
NI201000047A (es) 2010-09-09
MX2010003980A (es) 2010-11-09
CN101932323A (zh) 2010-12-29
JP2011502977A (ja) 2011-01-27

Similar Documents

Publication Publication Date Title
CR11473A (es) Uso de 3,11 b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
GT200500175A (es) Inhibidores de cetp
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
HN2009003002A (es) Compuestos de piridopirimidinonas inhibidores de pi3k-alfa
PA8774801A1 (es) Productos para el cuidado oral y metodos de uso y fabricacion de los mismos
GT200500158A (es) Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa
CL2008000795A1 (es) Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil)piperazina para el tratamiento del dolor o de los sintomas residuales de la depresion; y dicho compuesto.
UY32535A (es) Métodos e intermediarios para la preparación de agentes farmacéuticos
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
CR11099A (es) Uso de compuestos inhibidores de quinaxolina de p13k-alfa para el tratamiento del cancer
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
ECSP11011151A (es) Compuestos purina
CR11483A (es) Inhibidores de peptido desformilasa
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2008000896A1 (es) Composicion que mantiene el cuidado bucal periodico que comprende un aminoacido basico; uso en el tratamiento terapeutico de la superficie bucal.
AR056049A1 (es) 2-(2,6-dimetil-morfolin-4-il-n-[5-(6-morfolin-4-il-4-oxo-4h-piran-2-il)-9h-tioxanten-2-il]-acetamida,como inhibidor de la quinasa atm
CR20120171A (es) Uso de n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi) fenil)-4-(4-metil-2-tienil)-1-ftalazinamina en el tratamiento de cáncer resistente al agente antimitótico
CR11859A (es) Composición y proceso-356
UY31022A1 (es) Uso de fungicidas para el tratamiento de micosis en peces
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
UY30788A1 (es) Compuestos quimicos
CL2011000100A1 (es) Uso de un inhibidor de desacetilasa de histona para el tratamiento de la enfermedad de hodgkin.
MX350019B (es) Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-bencimidaz ol-4-carboxamida.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)